Literature DB >> 3709635

The absorption of piretanide from the gastro-intestinal tract is site-dependent.

D Brockmeier, H G Grigoleit, H Leonhardt.   

Abstract

The absorption of piretanide was investigated after placing the drug in the stomach, duodenum and ascending colon under visual control. The relative amounts absorbed and the rates of absorption were estimated from the area under the curve and the total mean time, respectively. Similar amounts of piretanide were absorbed and at almost the same rate after placement in the stomach and duodenum; the area under the curve for the stomach was 250 ng h/ml and for the duodenum 243 ng h/ml, the mean absorption times being 1.97 h and 1.51 h respectively. A marked difference was observed in the rate of from the ascending colon; the area amounted to 66 ng h/ml and the mean time to 3.99 h. Although area values for the colon were significantly different from those observed with the stomach and duodenum, it must be emphasised that the amount absorbed depends on the time the drug is in contact with the absorbing surface. There is discussion of whether the differences in absorption between the duodenum and colon can be explained by the physico-chemical properties of the drug alone, or whether the results reflect a saturable transport mechanism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709635     DOI: 10.1007/bf00614200

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  The gastric secretion of drugs: a pH partition hypothesis.

Authors:  P A SHORE; B B BRODIE; C A HOGBEN
Journal:  J Pharmacol Exp Ther       Date:  1957-03       Impact factor: 4.030

2.  [A simple statistical dosage metabolism law].

Authors:  F H DOST
Journal:  Klin Wochenschr       Date:  1958-07-15

3.  Absorption of glibenclamide from different sites of the gastro-intestinal tract.

Authors:  D Brockmeier; H G Grigoleit; H Leonhardt
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Retrograde colonic spread of sulphasalazine enemas.

Authors:  W Kruis; U Büll; J Eisenburg; G Paumgartner
Journal:  Scand J Gastroenterol       Date:  1982-10       Impact factor: 2.423

5.  In vitro-in vivo correlation, a time scaling problem? Evaluation of mean times.

Authors:  D Brockmeier
Journal:  Arzneimittelforschung       Date:  1984

6.  Vascular effects of piretanide. Studies on extrarenal action in several animal models.

Authors:  E Klaus; H G Alpermann; G Caspritz; W Linz; B Schölkens
Journal:  Arzneimittelforschung       Date:  1983

7.  Absorption of digoxin in man after oral and intrasigmoid administration studied by portal vein catheterization.

Authors:  K E Andersson; L Nyberg; H Dencker; J Göthlin
Journal:  Eur J Clin Pharmacol       Date:  1975-10-10       Impact factor: 2.953

8.  Absorption of digoxin from the distal parts of the intestine in man.

Authors:  H Ochs; G Bodem; P K Schäfer; G Kodrat; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

9.  A radioimmunoassay to measure piretanide in human serum and urine.

Authors:  W Heptner; S Baudner; E E Dagrosa; C Hellstern; R Irmisch; H Strecker; H Wissmann
Journal:  J Immunoassay       Date:  1984

10.  Absorption of enprofylline from the gastrointestinal tract in healthy subjects.

Authors:  E Lunell; K E Andersson; O Borgå; P O Fagerström; N Johannesson; G Kjellin; C G Persson; K Sjölund
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more
  9 in total

1.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Pharmacokinetic profile of a novel slow release preparation of molsidomine.

Authors:  S Rietbrock; B Keller-Stanislawski; P Thürmann; D Brockmeier
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.

Authors:  A B Suttle; G M Pollack; K L Brouwer
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

4.  Prediction of intestinal drug absorption properties by three-dimensional solubility parameters.

Authors:  J Breitkreutz
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

5.  Applications and simulations of a discontinuous oral absorption pharmacokinetic model.

Authors:  J W Witcher; F D Boudinot
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

6.  A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption.

Authors:  Y Plusquellec; G Campistron; S Staveris; J Barre; L Jung; J P Tillement; G Houin
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

7.  Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin.

Authors:  A A Somogyi; F Bochner; D Hetzel; D B Williams
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

8.  Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.

Authors:  Mourad Hamimed; Pierre Leblond; Aurélie Dumont; Florence Gattacceca; Emmanuelle Tresch-Bruneel; Alicia Probst; Pascal Chastagner; Anne Pagnier; Emilie De Carli; Natacha Entz-Werlé; Jacques Grill; Isabelle Aerts; Didier Frappaz; Anne-Isabelle Bertozzi-Salamon; Caroline Solas; Nicolas André; Joseph Ciccolini
Journal:  Cancer Chemother Pharmacol       Date:  2022-06-25       Impact factor: 3.288

9.  Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function.

Authors:  Yukiko Metsugi; Yoshihiro Miyaji; Ken-ichi Ogawara; Kazutaka Higaki; Toshikiro Kimura
Journal:  Pharm Res       Date:  2007-10-23       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.